Although the drug sensitivity of ARID1A-deficiency has been analyzed in ovarian cancer cell lines [39], no in vivo effectiveness of PI3K/AKT inhibitors for GC cells with ARID1A depletion has been addressed. The gene discussed is AKT1; the disease is ovarian carcinoma.